Skip Navigation



European Heart Journal Advance Access published online on June 16, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn262
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/16/2058    most recent
ehn262v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Garcia, R. G.
Right arrow Articles by López-Jaramillo, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia, R. G.
Right arrow Articles by López-Jaramillo, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus: when to start it?

Ronald G. Garcia

Grupo VILANO
Research Institute
Fundación Cardiovascular de Colombia
Calle 155a # 23–58, 3 piso
Floridablanca
Colombia
Facultad de Medicina Universidad de Santander [UDES]
Bucaramanga
Colombia

Patricio López-Jaramillo

Grupo VILANO
Research Institute
Fundación Cardiovascular de Colombia
Calle 155a # 23–58, 3 piso
Floridablanca
Colombia
Tel: +57 7 639 9292
Fax: +57 7 639 9623
Email: joselopez@fcv.org

The first 10% of the full text of this article appears below.

We have read with great interest the article by Mellbin et al.1 that reported an increased risk of non-fatal cardiovascular events in diabetic patients on insulin treatment with myocardial infarction. This epidemiological analysis also underlines the safety of the oral glucose-lowering agents in these patients, and found that metformin . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?